A Phase 2 study of MBX 1416 in patients with post-bariatric hypoglycemia (PBH)
Latest Information Update: 10 Jan 2025
Price :
$35 *
At a glance
- Drugs MBX 1416 (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors MBX Biosciences
- 10 Jan 2025 New trial record